Posting of 2023 Annual Report and Notice of AGM

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

18 December 2023 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company,
announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 July 2023 and Notice of the Annual General Meeting (“AGM”) which will be held at Panmure Gordon, 40 Gracechurch Street, EC3V 0BT, on 23 January 2024 at 11.30 a.m. (GMT).

The Annual Report and Accounts and Notice of AGM are also available to view on, and download from, the Company’s website at

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company, combining scientific expertise with
cutting-edge Drug Discovery technologies to efficiently deliver worldleading medicines. We have a highly
valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation. Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.

For more information visit us at or follow us on twitter @C4XDiscovery.